VISTN Stock Overview
Through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 23.70 |
| 52 Week High | NOK 28.80 |
| 52 Week Low | NOK 20.70 |
| Beta | 0.84 |
| 1 Month Change | 4.87% |
| 3 Month Change | -0.84% |
| 1 Year Change | 0.85% |
| 3 Year Change | 36.99% |
| 5 Year Change | 244.48% |
| Change since IPO | 25.40% |
Recent News & Updates
Recent updates
Vistin Pharma's (OB:VISTN) Upcoming Dividend Will Be Larger Than Last Year's
Feb 16
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26Shareholder Returns
| VISTN | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 0.9% | -2.5% | -0.3% |
| 1Y | 0.9% | -2.6% | 8.6% |
Return vs Industry: VISTN exceeded the Norwegian Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: VISTN underperformed the Norwegian Market which returned 8.6% over the past year.
Price Volatility
| VISTN volatility | |
|---|---|
| VISTN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 12.0% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: VISTN has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: VISTN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 75 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| VISTN fundamental statistics | |
|---|---|
| Market cap | NOK 1.05b |
| Earnings (TTM) | NOK 62.75m |
| Revenue (TTM) | NOK 429.50m |
16.7x
P/E Ratio2.4x
P/S RatioIs VISTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VISTN income statement (TTM) | |
|---|---|
| Revenue | NOK 429.50m |
| Cost of Revenue | NOK 149.97m |
| Gross Profit | NOK 279.53m |
| Other Expenses | NOK 216.78m |
| Earnings | NOK 62.75m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 65.08% |
| Net Profit Margin | 14.61% |
| Debt/Equity Ratio | 0% |
How did VISTN perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield88%
Payout RatioDoes VISTN pay a reliable dividends?
See VISTN dividend history and benchmarks| Vistin Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Jun 04 2025 |
| Dividend Pay Date | Jun 12 2025 |
| Days until Ex dividend | 108 days |
| Days until Dividend pay date | 116 days |
Does VISTN pay a reliable dividends?
See VISTN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:17 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |